Low molecular weight heparin in pregnancy: current issues

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Hematology

Background:

• Low molecular weight heparin (LMWH) is the preferred anticoagulant for venous thromboembolism (VTE) in pregnancy and postpartum in the UK.
• LMWH offers practical advantages over unfractionated heparin (UFH) due to predictable pharmacokinetics and less frequent dosing during pregnancy.
• Extensive use over a decade confirms LMWH's superior safety profile compared to UFH in obstetric patients.

Purpose of the Study:

• To address the lack of consensus among experts regarding LMWH use in pregnancy.
• To identify critical areas requiring further research and evidence-based guidelines for LMWH therapy in obstetric patients.
• To highlight the urgent need for well-designed clinical trials to inform clinical practice.

Main Methods:

• Review of existing literature, including small trials and observational studies.
• Analysis of expert opinions and anecdotal evidence informing current clinical practice.
• Identification of knowledge gaps in LMWH dosing, duration, and monitoring during pregnancy.

Main Results:

• Despite widespread use and established safety, significant disparities exist in expert recommendations for LMWH management in pregnancy.
• Current clinical practice is largely based on limited evidence, personal experience, and anecdote rather than robust data.
• Key uncertainties persist regarding optimal LMWH dosage, treatment duration, and the necessity and methods for therapeutic drug monitoring.

Conclusions:

• While LMWH is a safe and effective anticoagulant in pregnancy, current clinical guidelines lack a strong evidence base.
• Urgent need for high-quality randomized controlled trials to establish evidence-based protocols for LMWH use in pregnancy and the puerperium.
• Standardized approaches to LMWH dosing, duration, and monitoring are required to optimize VTE prophylaxis and treatment in obstetric care.